FDA Breakthrough Therapy Designation for Hypothalamic Obesity Drug Setmelanotide
ADC评论
November 3, 2022
On November 1, Rhythm Pharmaceuticals announced that its MC4R agonist setmelanotide was granted Breakthrough Therapy Designation by the FDA for the treatment of hypothalamic obesity.
